Niki BioSolutions, Inc. (NIKI) - Net Assets
Based on the latest financial reports, Niki BioSolutions, Inc. (NIKI) has net assets worth $13.79 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($18.69 Million) and total liabilities ($4.90 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. For live market cap and overall valuation, see Niki BioSolutions, Inc. (NIKI) total market value.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $13.79 Million |
| % of Total Assets | 73.79% |
| Annual Growth Rate | -9.34% |
| 5-Year Change | -21.22% |
| 10-Year Change | N/A |
| Growth Volatility | 73.09 |
Niki BioSolutions, Inc. - Net Assets Trend (2017–2025)
This chart illustrates how Niki BioSolutions, Inc.'s net assets have evolved over time, based on quarterly financial data.
Annual Net Assets for Niki BioSolutions, Inc. (2017–2025)
The table below shows the annual net assets of Niki BioSolutions, Inc. from 2017 to 2025. See Niki BioSolutions, Inc. (NIKI) balance sheet quality index to measure how much of total assets are equity-financed.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $13.79 Million | +17.11% |
| 2024-12-31 | $11.78 Million | -23.44% |
| 2023-12-31 | $15.38 Million | +96.38% |
| 2022-12-31 | $7.83 Million | -55.25% |
| 2021-12-31 | $17.51 Million | -54.12% |
| 2020-12-31 | $38.15 Million | +156.89% |
| 2019-12-31 | $14.85 Million | -54.65% |
| 2018-12-31 | $32.75 Million | +8.33% |
| 2017-12-31 | $30.23 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Niki BioSolutions, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7124533600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $80.00 | 0.00% |
| Other Comprehensive Income | $-92.31K | -0.40% |
| Other Components | $97.05 Million | 418.99% |
| Total Equity | $23.16 Million | 100.00% |
Niki BioSolutions, Inc. Competitors by Market Cap
The table below lists competitors of Niki BioSolutions, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bumi Citra Permai Tbk
JK:BCIP
|
$5.45 Million |
|
FENIXORO GOLD CORP.
F:8FD
|
$5.45 Million |
|
Samfine Creation Holdings Group Limited
NASDAQ:SFHG
|
$5.45 Million |
|
Cooper Metals Ltd
AU:CPM
|
$5.45 Million |
|
CodeLab Capital A/S
OL:CODE
|
$5.45 Million |
|
UPHEALTH INC
F:5XV
|
$5.44 Million |
|
London Security Plc
LSE:LSC
|
$5.44 Million |
|
Tedea Technological Development and Automation Ltd
TA:TEDE
|
$5.44 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Niki BioSolutions, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 21,134,514 to 23,162,160, a change of 2,027,646 (9.6%).
- Net loss of 1,363,270 reduced equity.
- New share issuances of 5,070,000 increased equity.
- Other comprehensive income decreased equity by 181,472.
- Other factors decreased equity by 1,497,612.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.36 Million | -5.89% |
| Share Issuances | $5.07 Million | +21.89% |
| Other Comprehensive Income | $-181.47K | -0.78% |
| Other Changes | $-1.50 Million | -6.47% |
| Total Change | $- | 9.59% |
Book Value vs Market Value Analysis
This analysis compares Niki BioSolutions, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.03x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $1004.09 | $8.58 | x |
| 2018-12-31 | $1186.47 | $8.58 | x |
| 2019-12-31 | $563.99 | $8.58 | x |
| 2020-12-31 | $1326.80 | $8.58 | x |
| 2021-12-31 | $673.92 | $8.58 | x |
| 2022-12-31 | $440.24 | $8.58 | x |
| 2023-12-31 | $549.57 | $8.58 | x |
| 2024-12-31 | $387.58 | $8.58 | x |
| 2025-12-31 | $315.05 | $8.58 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Niki BioSolutions, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -5.89%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.81x
- Recent ROE (-5.89%) is above the historical average (-39.61%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -8.42% | 0.00% | 0.00x | 1.04x | $-5.57 Million |
| 2018 | -44.79% | -3868.04% | 0.01x | 1.36x | $-18.14 Million |
| 2019 | -114.22% | -3491.81% | 0.02x | 1.46x | $-20.32 Million |
| 2020 | 16.89% | 775.31% | 0.02x | 1.06x | $2.88 Million |
| 2021 | -106.10% | -1624.38% | 0.07x | 0.93x | $-27.41 Million |
| 2022 | -62.37% | -756.17% | 0.06x | 1.33x | $-11.37 Million |
| 2023 | -11.37% | -654.88% | 0.02x | 0.83x | $-5.31 Million |
| 2024 | -20.19% | 0.00% | 0.00x | 0.76x | $-6.38 Million |
| 2025 | -5.89% | 0.00% | 0.00x | 0.81x | $-3.68 Million |
Industry Comparison
This section compares Niki BioSolutions, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $49,343,171
- Average return on equity (ROE) among peers: -63.98%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Niki BioSolutions, Inc. (NIKI) | $13.79 Million | -8.42% | 0.36x | $5.45 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $148.49 Million |
| Abcellera Biologics Inc (ABCL) | $11.61 Million | 2.66% | 0.85x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $335.61 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.59 Billion |
| Arbutus Biopharma Corp (ABUS) | $59.19 Million | -23.76% | 0.21x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $-2.99 Million | 0.00% | 0.00x | $23.14 Million |
| Abivax SA American Depositary Shares (ABVX) | $25.93 Million | -163.70% | 3.21x | $10.02 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $12.11 Million | -372.67% | 3.10x | $5.07 Billion |
About Niki BioSolutions, Inc.
Niki BioSolutions, Inc., through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in a Phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a r… Read more